Home / Sepsis Diagnosis and Management

Sepsis Diagnosis and Management

Know sooner, act faster

Read time: 5 minutes

Sepsis is a worldwide problem that can cause devastating patient consequences and drive significant healthcare costs. Research has shown that timely administration of antibiotics to patients with sepsis decreases the likelihood of death. However, as this syndrome encompasses a complex pathobiology, treatment may be delayed. Once conclusive evidence—such as organ failure—manifests, the severity of symptoms may have progressed and the risk of patient death may increase.

What if your physicians could act faster and avoid patient health deterioration? Find out how your laboratory can use interdisciplinary insights to support swifter action and better clinical outcomes.

Understanding Sepsis Get the facts on clinical sepsis, a costly and dangerous condition

A life-threatening syndrome

Sepsis is a dysregulated immune response to infection characterized by systemic inflammation. Infection leading to sepsis can start anywhere in the body, including the lungs, urinary tract, skin and abdomen. If not treated quickly and effectively, sepsis can progress to septic shock and lead to organ dysfunction and death.1


A global healthcare crisis

Sepsis affects more than 30 million people worldwide.1 Healthcare-related costs to manage sepsis total over $24 billion annually in the U.S.2 It is the leading cause of hospital readmissions1 and accounts for more hospitalization costs than any other disease.2


Timely treatment may save lives

Research indicates that the early and appropriate administration of antibiotics decreases sepsis mortality. There is an association between prompt antibiotics administration and improved outcomes in cases of both sepsis and septic shock.3

Early broad-spectrum antimicrobial administration is vital to improving outcomes for severely septic patients admitted through the emergency department (ED).4 For every hour that antibiotics are delayed after ED triage, at the beginning of organ dysfunction or at the onset of shock, there may be a 3% to 7% increase in the risk of unfavorable outcomes.3

Sepsis diagnosis remains difficult, due to insufficient sensitivity and specificity of tests and risk scores.5,6 

Identifying and treating sepsis earlier can also reduce the cost of sepsis-related care.7,8 

Supporting Better Outcomes Partner with the only company providing all currently available IVD testing disciplines that may be used to support sepsis diagnosis and management

Supporting better clinical outcomes in patients with possible sepsis or confirmed sepsis requires a broad and comprehensive approach. That's why, when it comes to sepsis diagnosis, it's important to have access to all in vitro diagnostic testing disciplines and management tools, including: 
  • An interdisciplinary portfolio of IVD testing solutions, comprising both common and unique tests, for all stages of the syndrome
  • Flexibility and breadth to support your institution’s specific sepsis management protocols
  • Laboratory connectivity and data management tools that automate and expedite delivery of time-critical results to clinicians 

Turning Knowledge Into Action Use interdisciplinary laboratory insights to support swift action

Testing for sepsis is done using many different biomarkers and systems belonging to different laboratory disciplines and there is no single, global standard of care.  

For septic patients, IVD testing can be crucial to support effective treatment. Our solutions aid in delivering laboratory insights that can speed-up decision making at every stage of the sepsis identification and treatment path. (See Figure 1. Note: While there are variations in the standard of care, this figure generally describes what an IVD testing path may look like.)

Sepsis Diagnosis Management Infographic

Download the full infographic ›

Figure 1. At every stage of the sepsis detection and treatment path, we offer clinical laboratory solutions that provide valuable diagnostic insights.


Suspect

Epidemiology studies show that 2/3 of septic patients enter the healthcare system via the ED.9 However, early sepsis detection in the ED is challenging, since patients show myriad symptoms that can be ambiguous and may point toward a variety of causes. This makes a concrete diagnosis difficult and may delay treatment.

Depending on an institution's protocols and a patient's symptoms, the following tests may be ordered. (Note: The list below may not be complete and does not describe any specific sequence in testing.)

  • CBC with differential and Early Sepsis Indicator: The Early Sepsis Indicator is an innovative test unique to our DxH 900 and DxH 690T hematology analyzers. This technology detects morphological changes in monocytes, cells of the innate immune system that provide a first line of defense against infections. Together with other laboratory findings and clinical information, the Early Sepsis Indicator provides clinicians with an alert as to the possibility of sepsis or risk of developing sepsis in adult patients entering the ED. Results are reported as part of the initial CBC with differential test, the laboratory test most rapidly available to clinicians
  • Basic or comprehensive metabolic panel: This frequently ordered panel comprising 14 tests gives clinicians insight into organ functions as well as the status of the patient’s metabolism
  • Urinalysis: According to the CDC, urinary tract infections account for 25% of sepsis cases.6 Testing urine samples can help identify whether infection is present in the urinary tract9
DxH 900 output buffer with cassettes purple tubes

Early Sepsis Indicator

Learn about the first early sepsis warning solution to be offered as part of a routine CBC with differential test, the Early Sepsis Indicator.

Learn more

Diagnose

Additional confirmatory and resistance testing may be ordered to confirm a diagnosis of sepsis.

  • Procalcitonin* (PCT): Procalcitonin is a biomarker for sepsis, and can be a powerful tool for insights when combined with other findings from the patient’s medical history, physical examination and other assessments. Our PCT assays enable laboratories to run PCT tests more efficiently
  • Lactate: Lactate results can complement the results of other tests, giving insight into the progression of illness, its severity and effectiveness of treatment
  • C-reactive protein (CRP) and interleukin-6 (IL-6*): These related biomarkers of inflammation can be useful in supporting early diagnosis of infection. CRP is widely used for adults, while IL-6 is used for neonates and infants
 
Access PCT reagent packs calibrators

Access PCT*†

Empower fast, accurate clinical decision making for patients with sepsis or suspected sepsis while simplifying your sample-processing flow and reducing the operational expenses associated with maintaining a separate, dedicated immunoassay workstation for PCT analysis.

Learn more
Procalcitonin Assay

PCT Assay† ‡ for Clinical Chemistry Analyzers

Adding PCT to the menu of your current Beckman Coulter clinical chemistry analyzer is an efficient way to offer sepsis testing in your laboratory without the need for a more expensive, dedicated platform.

Learn more

Confirm

Once a diagnosis of sepsis is reached, clinicians typically start treatment with broad-spectrum antibiotics while investigating the type of infection, identifying the exact pathogen responsible for the infection and determining a targeted course of antibiotics. 
 
  • Fast bacterial identification (ID): The industry-leading Bruker MALDI Biotyper® system provides rapid microbial identification. Together with the DxM WalkAway system and software, it can deliver accurate ID results within minutes to support proactive patient management
  • Antibiotic susceptibility testing (AST): MicroScan panels have the fewest clinically significant drug-pathogen limitations10 of all the major automated ID/AST methods, enabling more first-time reporting treatment options for septic patient therapy11  

Manage

Receiving actionable insights quickly from ongoing testing helps clinicians monitor treatment effectiveness to stop the progression of sepsis, resolve the infection and, ultimately, discharge the patient. 

Clinical informatics solution REMISOL Advance reports results to your laboratory, empowering you to deliver robust, standardized insights into sepsis for informed decision making. Automated reporting ranges and rules for Beckman Coulter IVD sepsis diagnosis and management tools are synchronized and preloaded within REMISOL Advance, saving you and your staff from time-consuming rule definition and writing. In addition, values and rules are customizable with just a few clicks, so you can tailor reporting to the specific sepsis treatment guidelines of your institution. 

Define Your Solution

How can your clinical laboratory help physicians know sooner and act faster? Our sepsis IVD portfolio can help. We can provide recommendations tailored to the needs of your patient population and institutional requirements.

1Sepsis Alliance. “Fact Sheet.2018.” Sepsis.org. Accessed 6 Mar. 2019.
2Torio C, Moore B. “National Inpatient Hospital Costs: The Most Expensive Conditions by Payer.” www.hcup-us.ahrq.gov/reports/statbriefs/sb204-Most-Expensive-Hospital-Conditions.pdf, May 2016. Accessed 15 Jan. 2018.
3Seymour CW et al. “Delays from First Medical Contact to Antibiotic Administration for Sepsis.” Crit Care Med 2017; 4595:759–765.
4Whiles BB, Deis AS and Simpson SQ. “Increased Time to Initial Antimicrobial Administration is Associated with Progression to Septic Shock in Severe Sepsis Patients.” Crit Care Med 2017; 45(4):623–629.
5Ljungström L et al. “Diagnostic Accuracy of Procalcitonin, Neutrophil-lymphocyte Count Ratio, C-reactive Protein, and Lactate in Patients with Suspected Bacterial Sepsis.”  PLoSONE 2017;12(7): e0181704.
6CDC Vital Signs, August 2016. www.cdc.gov/vitalsigns/pdf/2016-08-vitalsigns.pdf. Accessed 14 Mar. 2019. 
7Judd WR, Stephens DM, Kennedy DA. “Clinical and Economic Impact of a Quality Improvement Initiative to Enhance Early Recognition and Treatment of Sepsis.” Ann Pharmacol 2014; 48(10):1269–75.
8Filbin MR et al. “Presenting Symptoms Independently Predict Mortality in Septic Shock: Importance of a Previously Unmeasured Confounder.” Crit Care Med 2018; 46:1592–9.
9 Perman S M, Goyal M and Gaieski, DF. “Initial Emergency Department Diagnosis and Management of Adult Patients with Severe Sepsis and Septic Shock.” Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine 2012; 20:41. http://doi.org/10.1186/1757-7241-20-41.
10"Drugs of First and Second Choice.” The Medical Letter, 20th ed., 2015; CLSI, M100-ED29:2019 Performance Standards for Antimicrobial Susceptibility Testing, 29th ed.; product Instructions for Use; FDA 510(k) clearances; product recall notices.
11ServiceTrak Clinical Executive Summary Report for ID/AST Systems, 2016.


*Not available in all countries. Please contact your local Beckman Coulter representative for more information.
†CE marked. Pending 510(k) clearance by the U.S. FDA. Not yet available for in vitro diagnostic use in the U.S.
‡Manufactured by Diazyme Laboratories.

MALDI Biotyper is the property of Bruker Daltonik GmbH. 
REMISOL Advance is a trademark or registered trademark of Normand-Info SAS in the United States and other countries. Used under license.

Products
Support
Company Newsletter
Beckman Coulter Life Sciences

Information addressed to health professionals. The products presented on this site are for professional use only, and, where applicable, comply with the requirements of the IVD Directive 98/79 / EC. Instructions for use must be consulted before using these products.

 

© 2020 Beckman Coulter, Inc. All rights reserved. Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries. All other trademarks are the property of their respective owners.

U.S. Government Users Restricted Rights - As per GSA ADP Schedule Contract with Beckman Coulter, Inc., the use, duplication or disclosure is restricted as follows: Beckman Coulter hereby authorizes user to copy those documents published on the World Wide Web by Beckman Coulter, for noncommercial use, and only within the user's organization. Except as expressly provided above, nothing contained herein shall be construed as granting any license or right under any Beckman Coulter copyright. Nothing contained herein shall be construed as granting by implication, estoppel or otherwise any license or right under any patent or trademark of Beckman Coulter or any third party.